In noncardioembolic ischemic stroke or high-risk TIA, asundexian reduced ischemic stroke and did not increase major bleeding

The authors investigate whether asundexian can reduce the incidence of ischemic strokes in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attacks (TIAs) without increasing the risk of major bleeding. The findings suggest that asundexian effectively lowers the risk of ischemic stroke while maintaining a safety profile regarding major bleeding events.